Dolutegravir (DTG), an integrase strand transfer inhibitor (INSTI), is currently recommended for treatment initiation in antiretroviral-naı¨ve by most of clinical guidelines. Data from randomized trials demonstrated superiority of DTG over NNRTI and PI/r, supporting its clinical use especially in first-line regimens with high viral load, regardless of which NRTI pair (TDF/FTC or ABC/3TC) was initiated. Aim of this analysis was to describe DTG use in a representative unselected naı¨ve population in Italy and identify its determinants and patterns of prescription.
Titolo: | Prescription pattern and determinants of dolutegravir use in an antiretroviral-naive HIV-infected population in Italy: data from the ICONA Foundation Cohort Study. |
Autori: | PELLICANO', Giovanni Francesco [Membro del Collaboration Group] |
Data di pubblicazione: | 2016 |
Rivista: | |
Abstract: | Dolutegravir (DTG), an integrase strand transfer inhibitor (INSTI), is currently recommended for treatment initiation in antiretroviral-naı¨ve by most of clinical guidelines. Data from randomized trials demonstrated superiority of DTG over NNRTI and PI/r, supporting its clinical use especially in first-line regimens with high viral load, regardless of which NRTI pair (TDF/FTC or ABC/3TC) was initiated. Aim of this analysis was to describe DTG use in a representative unselected naı¨ve population in Italy and identify its determinants and patterns of prescription. |
Handle: | http://hdl.handle.net/11570/3142252 |
Appare nelle tipologie: | 14.d.1 Abstract in Atti di convegno |
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.